Nanobiotix Reports Encouraging Early Data and Funding for Cancer Therapy
Nanobiotix reported H1 2026 results, including promising early data from a Phase 1 study of JNJ-1900 in non-small cell lung cancer, with a 79% one-year locoregional control rate. The company raised approximately €86 million, extending its cash runway into 2029, and received FDA clearance for a protocol amendment in a Phase 3 head and neck cancer study. Cash and cash equivalents stood at €110.9 million as of June 30, 2026.
The Phase 1 trial, conducted at MD Anderson, enrolled 24 patients with inoperable recurrent non-small cell lung cancer who received the nanotherapeutic agent alongside re-irradiation. At 12 months median follow-up, the treatment achieved a 79% locoregional control rate, with investigators noting the approach allowed for substantially reduced radiation doses. No serious drug-related side effects emerged, and the recommended Phase 2 dose was set at 33% of gross tumor volume.
Financially, the company strengthened its position through an oversubscribed offering that raised roughly €86 million, extending operations into 2029. The firm also secured FDA approval for a protocol change in its Phase 3 head and neck cancer trial, and reported promising early signs from a separate Phase 2 study in Stage 3 unresectable NSCLC. Cash holdings stood at €110.9 million as of mid-2026.
This therapy's potential to enable effective cancer control with lower radiation doses could meaningfully improve quality of life for patients facing recurrent or advanced tumors, who often have limited options after standard treatments fail. If the encouraging early results hold in larger trials, the approach may expand treatment eligibility and reduce toxicity burdens. However, the data remain preliminary, and broader impact will depend on confirmatory Phase 3 outcomes and eventual regulatory approvals.